Effectiveness and safety of interleukin 6 receptor inhibitors versus conventional immunomodulatory therapy in steroid-refractory polymyalgia rheumatica
Anisha B. Dua(Brigham and Women's Hospital), Jeffrey R. Curtis(University of Alabama at Birmingham Hospital), Cassandra Calabrese(Cleveland Clinic), Danielle L. Isaman(Aetion (United States)), Natalia Petruski‐Ivleva(AVEO Oncology (United States)), K. Ford(Sanofi (United States)), Lita Araujo(Sanofi (United States)), Fenglong Xie(University of Advancing Technology), Ara Dikranian(Institute for Rheumatic Diseases (Japan)), Stefano Fiore(Morristown Medical Center), Clifton O Bingham(Johns Hopkins University), Robert Spiera(Cornell University)
Cited by 0
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis Care & Research|2015|1.1k
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
|The Lancet Diabetes & Endocrinology|2016|728
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254